"
Team:NTNU-Trondheim/Achievements
From 2013.igem.org
| Line 88: | Line 88: | ||
</div> | </div> | ||
| - | ===== | + | |
| + | <div class="row"> | ||
| + | <div class="col12-2" align = "justify"> | ||
| + | <div class="col8" align = "justify" style="background-color:#C3A7F3;> | ||
| + | <p style="text-align:center; color:black; "> BRONZE </p> </div> | ||
| + | <br><br> | ||
| + | <p> | ||
✔ 1.Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected. | ✔ 1.Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected. | ||
| Line 111: | Line 117: | ||
INCERT STUFF FROM VESICLES SAFETY FROM MARIA | INCERT STUFF FROM VESICLES SAFETY FROM MARIA | ||
| + | </p> | ||
| + | <div class ="row-end"> </div> | ||
| + | </div> | ||
| - | ==== | + | <div class="row"> |
| - | + | <div class="col12-2" align = "justify"> | |
| - | + | <div class="col8" align = "justify" style="background-color:#C3A7F3;> | |
| + | <p style="text-align:center; color:black; "> BRONZE </p> </div> | ||
| + | <br><br> | ||
| + | <p> | ||
✔ 1. Your project may have implications for the environment, security, safety and ethics and/or ownership and sharing. Describe a novel approach that your team has used to help you and others consider these aspects of the design and outcomes of synthetic biology efforts. Please justify its novelty and how this approach might be adapted and scaled for others to use. | ✔ 1. Your project may have implications for the environment, security, safety and ethics and/or ownership and sharing. Describe a novel approach that your team has used to help you and others consider these aspects of the design and outcomes of synthetic biology efforts. Please justify its novelty and how this approach might be adapted and scaled for others to use. | ||
Revision as of 13:00, 2 October 2013
✔ 1. Team registration
[https://igem.org/Team.cgi?year=2013&team_name=NTNU-Trondheim.com Registered Team]
✔ 2. Complete Judging Form
✔ 3. Team Wiki
[https://2013.igem.org/Team:NTNU-Trondheim NTNU's Wiki Home]
✔ 4. Present a poster and a talk at the iGEM Jamboree
✔ 5. Document at least one new standard BioBrick Part or Device used in your project/central to your project and submit this part to the iGEM Registry (submissions must adhere to the iGEM Registry guidelines). A new application of and outstanding documentation (quantitative data showing the Part’s/ Device’s function) of a previously existing BioBrick part in the “Experience” section of that BioBrick’s Registry entry also counts. Please note you must submit this new part to the iGEM Parts Registry
We submitted two new characterized BioBrick Parts:
1. BBa_K1082000 is a Pm/xylS promoter system is positively regulated by m-toluic acid. The m-toluic acid binds to the xylS protein which is constitutively expressed by the Pm/xylS promoter system. The xylS-m-toluic acid complex binds to the Pm promoter, and activates it.
2. BBa_K1082001 is a composite part that constitutively expresses a tat-GFP-RFP construct. It is a protein coding sequence coding a fusion protein made up by GFP and RFP. In addition, the part contains tat, a signaling sequence responsible for transport to the periplasm.
✔ 1.Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected.
:/ Pm/XylS ??
:/ Tat-GFP_RFP doen not work as expected! What can be said about this?
✔ 2.Document the characterization of this part in the “Main Page” section of that Part’s/Device’s Registry entry.
1. BBa_K1082000 is a Pm/xylS promoter system.
:/add something from results here
2. BBa_K1082001 is a tat-GFP-RFP construct.
:/add something from results here
✔ 3.Submit this new part to the iGEM Parts Registry (submissions must adhere to the iGEM Registry guidelines).
1.
✔ 1. Your project may have implications for the environment, security, safety and ethics and/or ownership and sharing. Describe a novel approach that your team has used to help you and others consider these aspects of the design and outcomes of synthetic biology efforts. Please justify its novelty and how this approach might be adapted and scaled for others to use. INCERT MARIAS STUFF ON VESICLES.
